Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-1.72%
|
$35,256
$104.1 P/Share
|
|
Feb 07
2015
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-0.57%
|
$26,300
$100.61 P/Share
|
|
Feb 07
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
259
-1.37%
|
$25,900
$100.61 P/Share
|
|
Jan 21
2015
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
703
+50.0%
|
$69,597
$99.5 P/Share
|
|
Jan 07
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
86,487
-73.32%
|
$8,216,265
$95.31 P/Share
|
|
Jan 07
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,487
+42.3%
|
$3,545,967
$41.17 P/Share
|
|
Jan 05
2015
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
144,144
-65.44%
|
$13,549,536
$94.3 P/Share
|
|
Jan 05
2015
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
144,144
+39.55%
|
$5,909,904
$41.17 P/Share
|
|
Jan 02
2015
|
Per Gh Lofberg EVP |
SELL
Open market or private sale
|
Direct |
347,343
-93.68%
|
$32,997,585
$95.28 P/Share
|
|
Jan 02
2015
|
Per Gh Lofberg EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
347,343
+48.37%
|
$15,630,435
$45.07 P/Share
|
|
Jan 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,240
-54.91%
|
$4,772,800
$95.71 P/Share
|
|
Jan 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,240
+35.45%
|
$1,708,160
$34.96 P/Share
|
|
Jan 02
2015
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
4,220
-59.97%
|
$400,900
$95.67 P/Share
|
|
Nov 07
2014
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
46,325
-45.56%
|
$4,076,600
$88.07 P/Share
|
|
Nov 07
2014
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
46,325
+31.21%
|
$1,760,350
$38.33 P/Share
|
|
Nov 06
2014
|
Per Gh Lofberg EVP |
SELL
Bona fide gift
|
Direct |
22,981
-49.53%
|
$2,022,328
$88.43 P/Share
|
|
Nov 05
2014
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
600
+18.65%
|
$52,200
$87.5 P/Share
|
|
Nov 05
2014
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,200
+50.0%
|
$104,400
$87.5 P/Share
|
|
Nov 05
2014
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,257
+5.09%
|
$283,359
$87.5 P/Share
|
|
Nov 05
2014
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,200
+6.49%
|
$104,400
$87.5 P/Share
|
|
Oct 27
2014
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
33,507
-33.27%
|
$2,848,095
$85.0 P/Share
|
|
Oct 27
2014
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,586
+27.05%
|
$1,103,440
$40.01 P/Share
|
|
Sep 02
2014
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
9,020
-56.17%
|
$712,580
$79.45 P/Share
|
|
Sep 02
2014
|
Andrew Sussman EVP, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
9,020
+35.97%
|
$324,720
$36.96 P/Share
|
|
Sep 01
2014
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
2,710
-27.8%
|
$214,090
$79.45 P/Share
|
|
Aug 22
2014
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
127
-0.4%
|
$10,033
$79.24 P/Share
|
|
Aug 08
2014
|
Larry J Merlo Director |
SELL
Bona fide gift
|
Direct |
30,966
-28.93%
|
$2,384,382
$77.81 P/Share
|
|
Aug 06
2014
|
J. David Joyner President and CEO |
SELL
Open market or private sale
|
Direct |
123,516
-56.68%
|
$9,387,216
$76.1 P/Share
|
|
Aug 06
2014
|
J. David Joyner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
123,516
+36.07%
|
$3,952,512
$32.17 P/Share
|
|
Jul 21
2014
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
22,107
-55.45%
|
$1,680,132
$76.77 P/Share
|
|
Jul 21
2014
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,107
+35.67%
|
$663,210
$30.16 P/Share
|
|
Jul 01
2014
|
David M Denton EVP and CFO |
SELL
Open market or private sale
|
Direct |
74,989
-46.33%
|
$5,624,175
$75.88 P/Share
|
|
Jul 01
2014
|
David M Denton EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
74,989
+21.01%
|
$2,549,626
$34.63 P/Share
|
|
May 12
2014
|
Larry J Merlo Director |
SELL
Bona fide gift
|
Direct |
10,000
-8.54%
|
$760,000
$76.82 P/Share
|
|
May 08
2014
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,756
+6.13%
|
$281,700
$75.86 P/Share
|
|
May 08
2014
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,384
+50.0%
|
$103,800
$75.86 P/Share
|
|
May 08
2014
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,384
+7.91%
|
$103,800
$75.86 P/Share
|
|
May 08
2014
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
692
+25.54%
|
$51,900
$75.86 P/Share
|
|
Apr 02
2014
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
17,108
-24.21%
|
$1,265,992
$74.51 P/Share
|
|
Apr 02
2014
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,108
+19.44%
|
$752,752
$44.85 P/Share
|
|
Apr 02
2014
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
19,210
-56.22%
|
$1,421,540
$74.02 P/Share
|
|
Apr 02
2014
|
Andrew Sussman EVP, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
19,210
+35.73%
|
$941,290
$49.8 P/Share
|
|
Apr 01
2014
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
8,412
+17.71%
|
$622,488
$74.29 P/Share
|
|
Apr 01
2014
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,095
+31.89%
|
$747,030
$74.29 P/Share
|
|
Apr 01
2014
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,749
+14.89%
|
$647,426
$74.29 P/Share
|
|
Apr 01
2014
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,166
-14.8%
|
$530,284
$74.29 P/Share
|
|
Apr 01
2014
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,038
+14.58%
|
$298,812
$74.29 P/Share
|
|
Apr 01
2014
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,203
-16.85%
|
$681,022
$74.29 P/Share
|
|
Apr 01
2014
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
110,095
+23.25%
|
$8,147,030
$74.29 P/Share
|
|
Apr 01
2014
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,857
-7.31%
|
$507,418
$74.29 P/Share
|